Articles Tagged: adolescents

2 articles found

England’s Under‑16 Energy Drink Ban: Practical Guidance for Parents, Schools, and Clinicians

England plans to prohibit sales of high‑caffeine energy drinks to children under 16, responding to concerns about sleep disruption, reduced concentration, classroom behaviour, and potential cardiovascular and neurological effects. The proposal would align age‑of‑sale rules with existing warning labels and long‑standing voluntary supermarket policies, restricting under‑16s’ access in shops, cafés, restaurants, vending machines, and online. A substantial minority of UK children consume energy drinks weekly, and teachers and clinicians report downstream problems from poor sleep to irritability and headaches. While most evidence is observational and does not establish causality, the policy aims to reduce exposure to high‑dose caffeine during critical developmental years. This article explains what the ban covers and when it could take effect, synthesizes the health evidence, and offers actionable guidance for parents, schools, and clinicians. We translate labels and caffeine equivalents into practical advice, flag clinical red flags and risk stratification considerations, and outline implementation issues for retailers and communities. We also indicate where evidence is strong, where it is limited, and what research questions remain.

energy drinkscaffeineadolescents+12 more

England & Wales to Offer Free Chickenpox Vaccine from Jan 2026 — What Parents, Schools and Clinicians Need to Know

England and Wales will introduce a free universal childhood varicella (chickenpox) vaccination programme beginning January 2026. This policy aligns the UK more closely with countries that have already reported substantial reductions in varicella incidence, hospitalizations and school outbreaks following universal childhood vaccination. Policymakers have weighed expected gains against long-discussed concerns about potential medium-term changes in herpes zoster (HZ, shingles) epidemiology due to reduced “exogenous boosting” of adult immunity. Dynamic modeling tailored to England and Wales projects large, durable reductions in varicella burden with universal vaccination, with only a modest, temporary uptick in HZ that later falls below baseline as vaccinated cohorts age. Real-world evidence from the United States and European regions adopting two-dose schedules corroborates strong public health impact with significant cuts in primary care visits, hospitalizations, and outbreaks, particularly in school settings. Clinicians, schools, and parents should prepare for updated vaccination schedules, catch-up pathways, documentation requirements, and pragmatic infection control as the programme rolls out. This brief synthesizes the clinical background of varicella-zoster virus (VZV), outlines diagnostic and management considerations, summarizes the evidence base for one- and two-dose strategies, and highlights surveillance priorities and operational implications for the NHS, schools, and families. It integrates UK-focused modeling, comparative international experience, and up-to-date surveillance and clinical trial signals.

varicellachickenpoxVZV+20 more